ArticlesNarrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial
Introduction
Atopic eczema is a common skin disease that usually arises in childhood, runs a relapsing and remitting course, frequently persists into adult life, and can result in significant morbidity. Emollients and topical steroids form the basis of treatment, but response is often incomplete. Second-line therapies such as ciclosporin and Chinese herbal medicine have been shown through randomised controlled trials to be effective.1, 2 However, there are concerns about safety.3, 4 Patients with atopic eczema often report improvement after sun exposure, and results from a series of studies suggest that ultraviolet B (UVB; wavelength 280-315 nm), ultraviolet A (UVA; 315–400 nm), and combined UVA-UVB are effective treatments.5, 6, 7 However, most of these studies involved patients with mild disease, few studies were randomised, and investigators did not always mask assessors so that they were unaware of treatment assignment.5 Furthermore, by contrast with clinical practice, topical therapy was limited to mild steroids and emollients.5 Findings of a randomised controlled trial8 have shown that high dose UVA1 (340–400 nm) is as effective as moderately potent topical steroids for acute, severe atopic eczema. However, special irradiation devices, which are only available in specialist centres, are needed for this type of treatment.
A narrow-band (311 nm) UVB fluorescent lamp (TL01, Philips, Utrecht, Netherlands) has been developed that is effective in the treatment of psoriasis.9, 10 Results of open, uncontrolled studies11, 12 suggest that narrow-band UVB phototherapy might improve chronic, severe adult atopic eczema. We designed a randomised, controlled, double-blind trial to assess efficacy of narrowband UVB and broad-band UVA (as used, for example, in psoralen photochemotherapy) as second-line, adjunctive treatment in adult patients with moderate to severe atopic eczema. These UV sources are widely available in dermatology practice.
Section snippets
Patients
Between April, 1995, and November, 1997, we enrolled patients, aged 16–65 years, who had been referred to a specialist assessment clinic at the Royal Victoria Infirmary, Newcastle upon Tyne, UK, by family physicians or dermatologists. Diagnosis of atopic eczema was based on the UK modification of Hanifin and Rajka's13 diagnostic criteria. We excluded patients if they had received narrow-band UVB or psoralen photochemotherapy, used sunbeds, or received systemic steroids, ciclosporin,
Results
Figure 1 shows the trial profile, and table 1 shows baseline characteristics. 73 patients fulfilled entry criteria and were allocated to a group. We excluded from analysis four patients who withdrew before treatment began. Thus, 69 patients commenced phototherapy. Patients in the narrow-band UVB group and in the broad-band UVA group received median cumulative doses of 24-8 J/cm2 (range 2·8–32·2) and 315 J/cm2 (15–345), respectively. Median cumulative exposure time to visible fluorescent lamps
Discussion
Our study results indicate that narrow-band UVB phototherapy is an effective adjunctive treatment in moderate-to-severe adult atopic eczema. Narrow-band UVB was better than placebo at reducing total disease activity, extent of disease, physician global assessment, and patient scoring of itch on a visual analogue scale. Furthermore, improvements in physician global assessment and total disease activity seen during treatment were maintained 3 months after phototherapy had been stopped. However,
References (33)
- et al.
Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis
Lancet
(1991) - et al.
Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis
Lancet
(1992) - et al.
Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study
J Am Acad Dermatol
(1990) - et al.
High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial
J Am Acad Dermatol
(1998) - et al.
Suberythemogenic narrow-band UVB is markedly more effective than conventional UVB in treatment of psoriasis vulgaris
J Am Acad Dermatol
(1999) - et al.
A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis
J Am Acad Dermatol
(1999) - et al.
Comparison of psoralen-UVB and psoralen-UVA photochemotherapy in the treatment of psoriasis
J Am Acad Dermatol
(1997) - et al.
Mechanisms of ultraviolet (UV) B and UVA phototherapy
J Investig Dermatol Symp Proc
(1999) - et al.
Suppressed alloantigen presentation, increased TNF-alpha, IL-1, IL-1Ra, IL-10, and modulation of TNF-R in UV-irradiated human skin
J Invest Dermatol
(1999) - et al.
The phototumorigenic potential of broad-band (270–350 nm) and narrow-band (311–313 nm) phototherapy sources cannot be predicted by their edematogenic potential in hairless mouse skin
J Invest Dermatol
(1995)
Carcinogenicity of UVB phototherapy assessed
Lancet
Traditional Chinese medicine for eczema: seemingly effective but caution must prevail
BMJ
Renal function after 10 years' treatment with cyclosporin for psoriasis
Br JDermatol
UVB phototherapy of atopic dermatitis
Br J Dermatol
UVA solarium versus UVB phototherapy of atopic dermatitis: a paired-comparison study
Br J Dermatol
A new development in UVB phototherapy of psoriasis
Br J Dermatol
Cited by (224)
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies
2024, Journal of the American Academy of DermatologySystemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
2023, Journal of Allergy and Clinical ImmunologyUltraviolet light induces mechanical and structural changes in full thickness human skin
2023, Journal of the Mechanical Behavior of Biomedical MaterialsA deep dive into UV-based phototherapy: Mechanisms of action and emerging molecular targets in inflammation and cancer
2021, Pharmacology and TherapeuticsPhototherapy for Itch
2020, Dermatologic Clinics